Loading
NASDAQHealthcareBiotechnology
Latest quote
$0.848
+$0.0496 · +6.21%
Biodexa Pharmaceuticals Plc, a biopharmaceutical company in the clinical development stage, is dedicated to advancing a diverse portfolio of products. Founded in 2000 and headquartered in Cardiff, United Kingdom, the company was formerly known as Midatech Pharma plc until its rebranding in March 2023. Its research and development efforts are focused on addressing significant unmet medical needs, including familial adenomatous polyposis, non-muscle invasive bladder cancer, Type 1 diabetes, and a spectrum of rare or orphan brain cancers. The company's primary drug candidate, Tolimidone, a selective activator of the lyn kinase enzyme, is currently undergoing Phase II clinical trials for the management of Type 1 diabetes. Additionally, Biodexa is progressing MTX110 through Phase I studies as an investigational treatment targeting specific challenging brain malignancies such as diffuse intrinsic recurrent glioblastoma, diffuse midline glioma, and medulloblastoma. Beyond its direct drug pipeline, Biodexa Pharmaceuticals also provides a suite of advanced drug delivery platforms designed to optimize therapeutic efficacy. These include Q-Sphera, a microtechnology utilizing polymer microspheres for controlled, sustained release of medications; MidaSolve, an oligosaccharide nanotechnology that facilitates the solubilization of drugs, enabling their direct and localized administration into tumor sites; and MidaCore, which employs gold nanoparticles for precise targeting of diseased areas, allowing for the delivery of either chemotherapeutic or immunotherapeutic agents. The company has established strategic collaboration agreements with pharmaceutical industry leaders Janssen and Melior.
Previous close
$0.848
+$0.0496 · +6.21%
Regular session · ET · Market data may be delayed.
Biodexa Pharmaceuticals Plc, a biopharmaceutical company in the clinical development stage, is dedicated to advancing a diverse portfolio of products. Founded in 2000 and headquartered in Cardiff, United Kingdom, the company was formerly known as Midatech Pharma plc until its rebranding in March 2023. Its research and development efforts are focused on addressing significant unmet medical needs, including familial adenomatous polyposis, non-muscle invasive bladder cancer, Type 1 diabetes, and a spectrum of rare or orphan brain cancers. The company's primary drug candidate, Tolimidone, a selective activator of the lyn kinase enzyme, is currently undergoing Phase II clinical trials for the management of Type 1 diabetes. Additionally, Biodexa is progressing MTX110 through Phase I studies as an investigational treatment targeting specific challenging brain malignancies such as diffuse intrinsic recurrent glioblastoma, diffuse midline glioma, and medulloblastoma. Beyond its direct drug pipeline, Biodexa Pharmaceuticals also provides a suite of advanced drug delivery platforms designed to optimize therapeutic efficacy. These include Q-Sphera, a microtechnology utilizing polymer microspheres for controlled, sustained release of medications; MidaSolve, an oligosaccharide nanotechnology that facilitates the solubilization of drugs, enabling their direct and localized administration into tumor sites; and MidaCore, which employs gold nanoparticles for precise targeting of diseased areas, allowing for the delivery of either chemotherapeutic or immunotherapeutic agents. The company has established strategic collaboration agreements with pharmaceutical industry leaders Janssen and Melior.
Day range
Current $0.848
52-week range
Current $0.848
Regular session · ET · Market data may be delayed.
AI-powered factor overview
GoAI Score
Sell
Trim exposure — unfavorable risk-reward
Valuation
46
Fair Value
Sentiment
55
Mixed
Risk
70
High Risk
Momentum
17
Strong Down
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Biodexa Pharmaceuticals Plc, a biopharmaceutical company in the clinical development stage, is dedicated to advancing a diverse portfolio of products. Founded in 2000 and headquartered in Cardiff, United Kingdom, the company was formerly known as Midatech Pharma plc until its rebranding in March 2023. Its research and development efforts are focused on addressing significant unmet medical needs, including familial adenomatous polyposis, non-muscle invasive bladder cancer, Type 1 diabetes, and a spectrum of rare or orphan brain cancers. The company's primary drug candidate, Tolimidone, a selective activator of the lyn kinase enzyme, is currently undergoing Phase II clinical trials for the management of Type 1 diabetes. Additionally, Biodexa is progressing MTX110 through Phase I studies as an investigational treatment targeting specific challenging brain malignancies such as diffuse intrinsic recurrent glioblastoma, diffuse midline glioma, and medulloblastoma. Beyond its direct drug pipeline, Biodexa Pharmaceuticals also provides a suite of advanced drug delivery platforms designed to optimize therapeutic efficacy. These include Q-Sphera, a microtechnology utilizing polymer microspheres for controlled, sustained release of medications; MidaSolve, an oligosaccharide nanotechnology that facilitates the solubilization of drugs, enabling their direct and localized administration into tumor sites; and MidaCore, which employs gold nanoparticles for precise targeting of diseased areas, allowing for the delivery of either chemotherapeutic or immunotherapeutic agents. The company has established strategic collaboration agreements with pharmaceutical industry leaders Janssen and Melior.
Day range
Current $0.848
52-week range
Current $0.848
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (GBP) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | — | — | 381K GBP | 699K GBP | 578K GBP |
| Cost of goods sold | 184.86K GBP | 5.44M GBP | 4.07M GBP | 5.11M GBP | 4.65M GBP |
| Gross profit | −184.86K GBP | −5.44M GBP | −3.69M GBP | −4.41M GBP | −4.08M GBP |
| Research and development | 3.73M GBP | 5.44M GBP | 4.07M GBP | 5.11M GBP | 4.65M GBP |
| Selling, general, and administrative | 4.84M GBP | 3.79M GBP | 4.34M GBP | 4.54M GBP | 2.95M GBP |
| Operating expenses | 8.08M GBP | 3.76M GBP | 4.33M GBP | 4.52M GBP | 2.92M GBP |
| Interest income | 87.05K GBP | 2K GBP | 83K GBP | 29K GBP | — |
| Interest expense | 68.47K GBP | — | 41K GBP | 53K GBP | 44K GBP |
| Depreciation and amortization | 184.86K GBP | 117K GBP | 283K GBP | 174K GBP | 403K GBP |
| Operating income | −8.27M GBP | −9.2M GBP | −8.01M GBP | −8.93M GBP | −7M GBP |
| Net income | −6.24M GBP | −5.73M GBP | −7.08M GBP | −7.66M GBP | −5.46M GBP |
Company facts updated Sep 5, 2026.
Recent quarterly results
Recent quarterly results
| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Apr 6, 2026 | 1:5 | — | — |
Stock split | Jul 31, 2025 | 1:10 | — | — |
Stock split | Oct 4, 2024 | 1:25 | — | — |
Stock split | Jul 5, 2023 | 1:80 | — | — |
Stock split | Mar 27, 2023 | 1:4 | — | — |
Stock split | Sep 26, 2022 | 1:5 | — | — |
Effective Apr 6, 2026
1:5
Effective Jul 31, 2025
1:10
Effective Oct 4, 2024
1:25
Effective Jul 5, 2023
1:80
Effective Mar 27, 2023
1:4
Effective Sep 26, 2022
1:5
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
